Molecular signatures of aggressive pediatric liver cancer

2021 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Liver Cancer ◽  
Molecular Signatures ◽  
Pediatric Liver

scholarly journals A Multidisciplinary Approach to Pediatric Liver Cancer Decreases Perioperative Complications and Improves Outcomes.

2020 ◽  
Author(s):  
Richard Whitlock ◽  
Sarah Jane Commander ◽  
Tu-Anh Ha ◽  
Huirong Zhu ◽  
Jorge Portuondo ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Multidisciplinary Approach ◽  
Perioperative Complications ◽  
Pediatric Liver

scholarly journals Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer

2021 ◽  
pp. candisc.1809.2020
Author(s):  
Theo Z Hirsch ◽  
Jill Pilet ◽  
Guillaume Morcrette ◽  
Amelie Roehrig ◽  
Benedict JE Monteiro ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Genomic Analysis ◽  
Driver Genes ◽  
Pediatric Liver

scholarly journals Liver Transplantation for Pediatric Liver Cancer

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 720 ◽  
Author(s):  
Rakesh Sindhi ◽  
Vinayak Rohan ◽  
Andrew Bukowinski ◽  
Sameh Tadros ◽  
Jean de Ville de Goyet ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Cancer ◽  
Liver Tumors ◽  
Current Knowledge ◽  
Tumor Staging ◽  
Steady Increase ◽  
Malignant Rhabdoid Tumor ◽  
Diagnostic Uncertainty ◽  
Pediatric Liver ◽  
Improvement In Survival

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.

61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma

2014 ◽  
Vol 50 ◽  
pp. 25
Author(s):  
M. Fabre ◽  
D. Nicolle ◽  
A. Gorse ◽  
O. Déas ◽  
C. Mussini ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patient ◽  
Pediatric Liver ◽  
Liver Cancer Patient

scholarly journals IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors

2012 ◽  
Vol 11 (1) ◽  
pp. 9 ◽  
Author(s):  
Ivonne Regel ◽  
Melanie Eichenmüller ◽  
Saskia Joppien ◽  
Johanna Liebl ◽  
Beate Häberle ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Metastatic Tumors ◽  
Pediatric Liver

scholarly journals C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer

Hepatology ◽  
2018 ◽  
Vol 67 (5) ◽  
pp. 1857-1871 ◽  
Author(s):  
Ashley Cast ◽  
Leila Valanejad ◽  
Mary Wright ◽  
Phuong Nguyen ◽  
Anita Gupta ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Pediatric Liver

Immunotargeting chemotherapy for AFP-producing pediatric liver cancer using the conjugates of anti-AFP antibody and anti-tumor agents

1992 ◽  
Vol 27 (6) ◽  
pp. 724-727 ◽  
Author(s):  
Yoshinobu Hata ◽  
Naoyuki Takada ◽  
Fumiaki Sasaki ◽  
Takeshi Abe ◽  
Hiromi Hamada ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Pediatric Liver ◽  
Immunotargeting Chemotherapy

scholarly journals Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer

2016 ◽  
Vol 65 (2) ◽  
pp. 325-333 ◽  
Author(s):  
Beatrice Bissig-Choisat ◽  
Claudia Kettlun-Leyton ◽  
Xavier D. Legras ◽  
Barry Zorman ◽  
Mercedes Barzi ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cell Line ◽  
Patient Derived Xenograft ◽  
Pediatric Liver

Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

Hepatology ◽  
2016 ◽  
Vol 64 (4) ◽  
pp. 1121-1135 ◽  
Author(s):  
Delphine Nicolle ◽  
Monique Fabre ◽  
Marina Simon-Coma ◽  
Aurore Gorse ◽  
Roland Kappler ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Clinical Management ◽  
Tumor Recurrence ◽  
Pediatric Liver ◽  
Predict Tumor Recurrence

scholarly journals Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin

2021 ◽  
Vol 12 ◽  
Author(s):  
Amber M. D’Souza ◽  
Ashley Cast ◽  
Meenasri Kumbaji ◽  
Maria Rivas ◽  
Ruhi Gulati ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Liver Cancer ◽  
Cancer Cells ◽  
Biological Activities ◽  
Tumor Suppressor Proteins ◽  
Pediatric Liver ◽  
Poor Outcomes ◽  
Relapsed Disease ◽  
Different Doses

Objective: Relapsed hepatoblastoma (HBL) and upfront hepatocellular carcinoma (HCC) are notoriously chemoresistant tumors associated with poor outcomes. Gankyrin (Gank) is a known oncogene that is overexpressed in pediatric liver cancer and implicated in chemo-resistance. The goal of this study was to evaluate if the Gank-tumor suppressor axis is activated in chemoresistant hepatoblastoma patients and examine if an inhibitor of Gank, Cjoc42, might improve the chemosensitivity of cancer cells.Methods: Expression of Gank and its downstream targets were examined in fresh human HBL samples using immunostaining, QRT-PCR, and Western Blot. Cancer cells, Huh6 (human HBL) and Hepa1c1c7 (mouse HCC) were treated with Cjoc42 and with Cjoc42 in combination with cisplatin or doxorubicin. Cell proliferation, apoptosis, and chemoresistance were examined. To examine activities of Cjoc42 in vivo, mice were treated with different doses of Cjoc42, and biological activities of Gank and cytotoxicity of Cjoc42 were tested.Results: Elevation of Gank and Gank-mediated elimination of TSPs are observed in patients with minimal necrosis after chemotherapy and relapsed disease. The treatment of Huh6 and Hepa1c1c7 with Cjoc42 was not cytotoxic; however, in combination with cisplatin or doxorubicin, Cjoc42 caused a significant increase in cytotoxicity compared to chemotherapy alone with increased apoptosis. Examination of Cjoc42 in WT mice showed that Cjoc42 is well tolerated without systemic toxicity, and levels of tumor suppressors CUGBP1, Rb, p53, C/EBPα, and HNF4α are increased by blocking their Gank-dependent degradation.Conclusions: Our work shows that Cjoc42 might be a promising adjunct to chemotherapy for the treatment of severe pediatric liver cancer and presents mechanisms by which Cjoc42 increases chemo-sensitivity.

Sign in / Sign up

Export Citation Format

Share Document